# A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

> **NCT01609010** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 313 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** rituximab
- **DRUG:** interferon-a-2a

## Key facts

- **NCT ID:** NCT01609010
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2014-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01609010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01609010, "A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01609010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*